Release – Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Research News and Market Data on TNXP

March 27, 2025 7:00am EDT
Download as PDF

CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present a poster at the AAPM 2025 Annual Meeting, PainConnect, in Austin, Texas on April 5, 2025, at 11:45 a.m. CT. The meeting will take place from April 3-6, 2025.

A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the conference website.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Peter Vozzo
ICR Healthcare
peter.vozzo@icrhealthcare.com
(443) 213-0505

Media Contact

Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432

Indication and Usage

Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.

Important Safety Information

Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:

  • discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace or Tosymra if you have:

  • history of heart problems
  • narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
  • uncontrolled high blood pressure
  • hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
  • had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
  • severe liver problems
  • taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
  • are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
  • an allergy to sumatriptan or any of the components of Zembrace or Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.

Zembrace and Tosymra may cause serious side effects including:

  • changes in color or sensation in your fingers and toes
  • sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
  • cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
  • increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
  • medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
  • serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
  • hives (itchy bumps); swelling of your tongue, mouth, or throat
  • seizures even in people who have never had seizures before

The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.

This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released March 27, 2025

Release – Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Research News and Market Data on Gyre Therapeutics

March 27, 2025

PDF Version

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial” in the Journal of Clinical and Translational Hepatology. This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B (“CHB”). The published protocol outlines patient inclusion criteria, randomization and blinding processes, key assessments, and the statistical analysis plan.

The randomized, double-blind, placebo-controlled, multicenter Phase 3 trial (NCT05115942) completed the enrollment of 248 patients across 44 clinical research hospitals in the People’s Republic of China (“PRC”) in October 2024. Patients were randomized 1:1 to receive either F351 or placebo in addition to entecavir antiviral basic therapy for CHB. The primary endpoint is a decrease in liver fibrosis (as measured by the Ishak Scoring System) by at least one stage after 52 weeks of treatment relative to baseline.

The PRC’s National Medical Products Administration (“NMPA”) designated F351 as a “Breakthrough Therapy” in 2021. Gyre expects to report topline results from this Phase 3 trial in the second quarter of 2025.

About Hydronidone (F351)

F351 is a next-generation anti-fibrotic compound and a structural analogue of Pirfenidone, the first approved treatment for idiopathic pulmonary fibrosis (“IPF”) in Japan, the European Union, the United States and the PRC. F351’s dual mechanism has been shown to inhibit in vitro p38γ kinase activity and TGF-β1-driven collagen overproduction—both key drivers of liver fibrosis. F351 specifically targets hepatic stellate cells (“HSCs”), which are central to the progression of fibrosis. In preclinical studies, it has shown strong anti-proliferative and anti-fibrotic effects on HSCs. These effects have been validated across multiple in vivo models of liver fibrosis, including CCl4-induced liver fibrosis in mice, DMN- and HSA-induced liver fibrosis in rats, and a mouse model of MASH fibrosis (a form of MASH with fibrosis) induced by CCl4 plus a Western high-fat diet. Together, these results highlight F351’s potential as a differentiated treatment for liver fibrosis, with a unique mechanism and strong preclinical and clinical evidence supporting its advancement into later-stage development.

About Gyre Pharmaceuticals

Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2024 net sales of $105.8 million). In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by Q2 2025. F351 received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, DKD, COPD, PAH and ALF/ACLF. In October 2023, Gyre Therapeutics acquired an indirect majority interest in Gyre Pharmaceuticals (also known as Beijing Continent Pharmaceuticals Co., Ltd.).

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in MASH is based on the company’s experience in MASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the expectations regarding Gyre’s research and development efforts and timing of expected clinical readouts, including timing of topline data from Gyre Pharmaceuticals’ Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings the Company may make with the Securities and Exchange Commission.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

For Investors:
Stephen Jasper
stephen@gilmartinir.com

Waraba Gold to Acquire Stake in Somaco Global Resources in Ivory Coast

Key Points Summary:
– Waraba Gold is acquiring up to an 80% stake in Somaco Global Resources, gaining access to prospective gold and manganese licences in northern Ivory Coast.
– The deal involves a $500,000 initial payment, $1.5 million over two years, and $5 million in exploration commitments, alongside issuing six million common shares.
– Waraba has suspended operations in Mali due to security concerns but remains committed to resuming activities when conditions improve.

Canadian mineral exploration company Waraba Gold has entered into an earn-in agreement to acquire up to an 80% stake in Somaco Global Resources, a move that strengthens its footprint in the West African mining sector. Somaco Global holds two highly prospective gold licence applications in northern Ivory Coast, a region known for its rich mineral deposits. These include the Sirasso licence and the Tengrela & Tiegba licences, both located near existing gold mines and mineralized shear zones.

One of the most significant assets in this deal is the Sirasso licence, covering 369.34km² in the Senoufou greenstone belt, an area recognized for its high gold potential. This licence was previously held in a joint venture (JV) with Barrick Gold, one of the world’s leading gold producers. Historically, greenstone belts have yielded high-grade gold deposits, and the Senoufou belt is no exception. Waraba’s investment signals confidence in the region’s potential for large-scale gold discoveries.

In addition to Sirasso, Waraba Gold gains access to the Tengrela & Tiegba licences, which span a combined area of nearly 767km². These licences are not only prospective for gold but also manganese, a critical mineral in steel production and battery technologies. The proximity of these licences to existing gold mines further enhances their exploration potential.

Under the terms of the agreement, Waraba Gold will gradually acquire an 80% stake in Somaco Global Resources over four years. The investment involves an initial payment of $500,000 to Somaco’s shareholders within the next two months, an additional $1.5 million to be paid over a two-year period, exploration commitments totaling $5 million over the next four years, and the issuance of six million common shares to Somaco shareholders upon the signing of a definitive joint venture agreement.

To finance the initial commitments, Waraba Gold announced plans to raise up to $500,000 through non-convertible unsecured debentures. These funds will also provide general working capital for the company’s operations. In addition, Waraba Gold will appoint two Somaco nominees as directors, further integrating the companies and ensuring a strategic partnership moving forward.

Alongside the Ivory Coast expansion, Waraba Gold provided an update on its Mali operations, revealing that it has temporarily suspended activities at the Fokolore Gold Project due to security concerns. Despite setbacks, Waraba remains committed to the Malian mining sector, having submitted a letter of intent for a mining permit in June 2024. However, with ongoing political instability, the company is waiting for conditions to improve before resuming full-scale operations.

West Africa has emerged as one of the fastest-growing gold mining regions globally, attracting major industry players. However, political uncertainties in countries like Mali have raised concerns among investors. Recently, CEOs of leading gold mining companies stated that Mali’s new mining code requires adjustments to encourage further foreign investment. Regulatory changes will play a crucial role in shaping the future of the region’s mining industry.

Waraba Gold’s agreement with Somaco Global Resources marks a strategic expansion into the Ivory Coast, an increasingly important gold-producing nation. By securing access to high-potential licences, Waraba is positioning itself for long-term growth in the West African mining sector. With ongoing fundraising efforts and a commitment to exploration, Waraba Gold aims to unlock significant value from its new assets. However, challenges in Mali and broader market uncertainties may still impact the company’s overall trajectory in the coming years.

Trump to Announce New Auto Tariffs as Trade War Escalates

Key Points:
– President Trump is set to unveil new auto tariffs, adding to a series of trade measures aimed at reshaping U.S. trade policy.
– The White House has confirmed retaliatory tariffs will be applied to several key trading partners.
– Global markets are reacting to uncertainty over the scope of these tariffs and their economic impact.

President Donald Trump is set to announce a fresh round of tariffs on auto imports later today, marking another escalation in his administration’s aggressive trade policy. These tariffs come as part of a broader effort to impose retaliatory duties on U.S. trading partners, a move that could significantly impact global trade dynamics.

The announcement follows weeks of speculation regarding which countries will be affected and to what extent. Trump has hinted at providing “a lot of countries breaks,” while also signaling that he does not want “too many” exemptions. The market is closely watching which nations will fall into the “dirty 15” category—those with trade imbalances deemed unfavorable to the United States.

The latest tariffs on automobiles add to an already sweeping list of trade measures enacted by the Trump administration. Earlier this month, a 25% tariff on steel and aluminum imports went into effect, impacting businesses across multiple industries.

The European Union responded swiftly, announcing counter-tariffs on $28 billion worth of U.S. goods. However, implementation has been staggered, with some key measures, like a 50% tariff on American whiskey, delayed until mid-April. This delay has sparked further uncertainty, with Trump threatening a 200% tariff on European spirits in retaliation.

Trump’s trade policies have already significantly impacted Canada and Mexico. As of March 4, the U.S. imposed a 25% tariff on all imports from its neighbors. However, a temporary pause was granted for goods and services that comply with the United States-Mexico-Canada Agreement (USMCA). This exemption is set to expire on April 2, leaving room for renegotiation.

In response, Canada introduced new tariffs on $20 billion worth of U.S. goods, further complicating trade relations. With both countries agreeing to reopen trade discussions, businesses on both sides of the border are bracing for potential disruptions.

Tensions between the U.S. and China remain high as Trump enforces new blanket tariffs of around 20% on top of the existing 10% duties from his first term. China has retaliated with up to 15% duties on U.S. agricultural products, including chicken and pork, which took effect on March 10.

Meanwhile, Venezuela has been targeted with a “secondary tariff” set to take effect on April 2. Under this measure, any country that buys oil or gas from Venezuela will face a 25% tariff when trading with the U.S. This move is expected to isolate Venezuela further while also impacting global energy markets.

The uncertainty surrounding these tariffs is already causing volatility in global markets. Investors are concerned about potential supply chain disruptions, rising costs for consumers, and retaliatory actions from key U.S. trade partners. The auto industry, in particular, could see increased costs, which may trickle down to car buyers in the form of higher prices.

As Trump’s trade war escalates, businesses and investors alike are preparing for a potentially turbulent economic landscape. With April 2—dubbed “Liberation Day” by Trump—fast approaching, all eyes are on the White House for further developments.

GameStop Stock Surges After Announcing Bitcoin Investment Plan

Key Points:
– GameStop’s board has approved Bitcoin as a treasury reserve asset, following speculation about the company’s interest in cryptocurrency.
– The stock jumped nearly 13% in premarket trading after the announcement.
– Analysts remain skeptical, comparing the move to MicroStrategy’s Bitcoin strategy, but questioning its long-term impact on GameStop’s stock.

GameStop (NYSE: GME), the video game retailer-turned-meme stock, saw its shares surge nearly 13% in premarket trading on Wednesday after confirming plans to allocate a portion of its cash reserves to Bitcoin. The move signals yet another pivot for the company as it looks to redefine its business strategy and capture investor interest amid ongoing challenges in the retail gaming sector.

In a statement released Tuesday, GameStop announced that its board of directors unanimously approved an update to its investment policy, officially allowing the company to purchase and hold Bitcoin as a treasury reserve asset. This decision follows weeks of speculation, fueled in part by a cryptic social media post from GameStop Chairman Ryan Cohen in early February, featuring a meeting with MicroStrategy CEO Michael Saylor, a well-known Bitcoin advocate.

GameStop’s announcement aligns it with MicroStrategy (NASDAQ: MSTR), a company that has aggressively invested in Bitcoin as part of its corporate treasury strategy. MicroStrategy currently holds over 447,000 Bitcoin, a move that has significantly boosted its stock price during Bitcoin bull runs.

The decision to invest in Bitcoin represents a major strategic shift for GameStop, which has struggled to define a clear business model in recent years. Following its infamous Reddit-fueled short squeeze in 2021, GameStop has experimented with NFT marketplaces, digital asset wallets, and e-commerce expansions, but none have significantly altered its financial trajectory.

While Bitcoin has seen strong gains in 2024 and 2025, GameStop’s move raises questions about its long-term financial strategy. Unlike MicroStrategy, which transformed itself into a Bitcoin-centric company, GameStop remains primarily a retail business with declining revenue. The company’s fourth-quarter earnings report, also released Tuesday, revealed a 28% decline in net sales year-over-year, further emphasizing the financial struggles it faces.

Despite the stock’s rally, analysts remain divided on whether GameStop’s Bitcoin investment will provide meaningful value. Wedbush analyst Michael Pachter voiced concerns about the decision, noting that MicroStrategy trades at approximately twice the value of its Bitcoin holdings, meaning that even a full allocation of GameStop’s $4.6 billion cash reserves into Bitcoin may not provide the same level of stock appreciation.

Additionally, Bitcoin’s volatility presents a risk for GameStop, which is already navigating declining brick-and-mortar sales, shifting consumer preferences, and increased digital gaming competition. A sudden drop in Bitcoin’s price could negatively impact GameStop’s financial position, leaving it with fewer options to reinvest in its core business.

GameStop’s Bitcoin strategy will likely fuel speculation and volatility in its stock price, much like previous meme stock cycles. However, whether this move translates into long-term value remains uncertain. Investors will be watching closely to see how GameStop executes its Bitcoin investment plan and whether it adopts a broader digital asset strategy beyond cryptocurrency holdings.

For now, the announcement has given GameStop bulls a new reason to rally, but the company’s future remains uncertain as it bets on Bitcoin to help redefine its financial outlook.

Americans’ Economic Expectations Plunge to 12-Year Low Amid Uncertainty

Key Points:
– The consumer expectations index fell to 65.2, its lowest level in 12 years, signaling rising concerns about financial stability and economic conditions.
– Inflation expectations jumped to 6.2% in March, with fewer consumers optimistic about the stock market.
– Despite declining sentiment, economists and the Federal Reserve remain cautious about whether pessimism will translate into lower spending.

Americans’ confidence in the economy has fallen to its lowest level in over a decade, reflecting heightened concerns over inflation, financial uncertainty, and the impact of President Donald Trump’s economic policies. The latest consumer confidence index from the Conference Board dropped to 92.9 in March, down from 100.1 in February, marking the lowest reading in more than four years.

More concerning is the expectations index—a measure of consumers’ outlook on income, business conditions, and employment—which plunged to 65.2, its weakest level since 2013. This marks the second consecutive month the index has remained below 80, a level historically associated with an impending recession.

The biggest driver of the decline appears to be worsening personal financial expectations. Consumers are increasingly pessimistic about their future earnings and job security, with financial situation expectations hitting their lowest level in over two years.

Inflation remains a primary concern, with consumer expectations for price increases rising to 6.2% in March from 5.8% in February. This shift suggests that Americans anticipate higher costs for everyday goods and services in the months ahead.

At the same time, consumer optimism about the stock market has deteriorated. For the first time since 2023, more Americans expect stocks to decline rather than rise, with only 37.4% of respondents predicting market gains over the next year. This shift in sentiment could indicate broader concerns about economic volatility and the impact of recent policies on financial markets.

While these fears weigh on economic confidence, the labor market remains a bright spot. Among the five components of consumer confidence measured in the survey, only current job market conditions showed improvement in March. This suggests that while Americans are worried about inflation and market stability, they are not yet seeing widespread job losses.

While consumer sentiment is declining, the critical question remains: Will this pessimism lead to reduced spending and a slowdown in economic growth? So far, Federal Reserve officials and economists are unsure.

Fed Chair Jerome Powell acknowledged the disconnect between consumer surveys and actual economic behavior, noting that while people express concern about the economy, they often continue spending on major purchases like cars and homes. “The relationship between survey data and actual economic activity hasn’t been very tight,” Powell said in a recent press conference.

Economists at Morgan Stanley have also downplayed fears of an imminent recession, arguing that consumer spending remains resilient. While retail sales dipped in January, they rebounded in February, casting doubt on the notion that a major downturn is underway.

If consumer confidence continues to decline, it could eventually translate into lower spending, which would have significant implications for businesses and economic growth. However, for now, the broader economic data suggests that while uncertainty is high, the economy remains relatively stable. The coming months will be crucial in determining whether Americans’ pessimism is justified or if the economy can weather the storm.

US Bond Investors Assess Convexity Risk as Treasury Yields Decline

Key Points:
– Falling Treasury yields have triggered increased convexity hedging by mortgage investors and insurers.
– The spread between 10-year swap rates and Treasury yields has tightened, indicating rising demand for fixed-rate protection.
– Convexity-driven market activity may amplify rate movements and impact broader financial markets.

The recent decline in U.S. Treasury yields has sparked renewed interest in “convexity” hedging, a strategy employed by mortgage portfolio managers, insurance companies, and institutional investors to adjust their risk exposure. As yields have dropped to their lowest levels since October, analysts suggest that significant convexity-related buying has played a role in accelerating the decline.

The benchmark U.S. 10-year Treasury yield, which serves as a key barometer for borrowing costs across the economy, bottomed at 4.10% on March 4 after a notable 56-basis-point drop since early February. While the yield has stabilized in recent weeks, it fell again by 18 basis points from March 13 to 4.17% on March 20, raising speculation about continued hedging activity.

Convexity refers to how changes in interest rates disproportionately affect bond prices and portfolio durations. Mortgage-backed securities (MBS) are particularly sensitive to convexity risks because mortgage holders tend to refinance their loans when rates fall, leading to an increase in early repayments. This shortens the expected duration of mortgage bonds, reducing their yield and leaving investors with less exposure to fixed income than they initially planned.

To counterbalance this effect, institutional investors—such as insurance firms, pension funds, and mortgage servicers—purchase Treasuries, Treasury futures, or interest rate swaps to maintain their portfolio durations. This rush to hedge can create a feedback loop, pushing Treasury yields lower and further increasing the need for convexity hedging.

Recent data indicates that convexity hedging has intensified, influencing key financial indicators:

  • Tightening Swap Spreads: The spread between 10-year interest rate swaps and 10-year Treasury yields has become more negative, with swap rates declining due to increased demand for fixed-rate protection. As of March 25, U.S. 10-year swap spreads had narrowed to -44 basis points from -38.3 basis points on February 14.
  • Increased Options Market Activity: Short-term implied volatility on longer-dated swaps has risen sharply, with three-month implied volatility on 10-year swap rates hitting a four-month high of 27.71 basis points on March 10 before settling at 25 basis points.
  • Hedging Demand from Mortgage Investors: While 64% of outstanding U.S. mortgages are locked in at rates below 4%, about 16% have rates above 6% and could be refinanced quickly if interest rates continue to fall, increasing the need for further hedging.

Convexity hedging can create self-reinforcing cycles that amplify rate moves. When Treasury yields fall sharply, increased buying by mortgage investors and insurers can push them even lower. Conversely, if rates rise unexpectedly, convexity hedging could shift in the opposite direction, triggering selling pressure that accelerates rate increases.

For insurance companies, falling yields present a profitability challenge, as lower rates reduce returns on their fixed-income investments. This can impact both policyholder returns and shareholder earnings.

Moreover, heightened market volatility—particularly around the Trump administration’s evolving trade and tariff policies—has contributed to elevated uncertainty in interest rate markets. Investors are closely watching Federal Reserve policy signals, as unexpected rate cuts or macroeconomic shifts could further accelerate convexity-driven market moves.

While active convexity hedging has declined from its peak in the early 2000s—when 27% of mortgage investors actively adjusted their portfolios compared to just 6% today—it still plays a meaningful role in driving short-term Treasury yield fluctuations. With continued uncertainty over economic growth and inflation trends, convexity hedging is likely to remain a key factor influencing fixed-income markets in the months ahead.

23andMe Files for Bankruptcy as Anne Wojcicki Steps Down as CEO

Key Points:
– Genetic testing company 23andMe has filed for Chapter 11 bankruptcy, struggling with declining revenue, cybersecurity concerns, and failed business expansions.
– Anne Wojcicki has resigned as CEO, with Joseph Selsavage stepping in as interim CEO.
– The company aims to sell its assets through a court-approved process, while Wojcicki has expressed interest in bidding to regain control.

Once a trailblazer in consumer DNA testing, 23andMe has filed for Chapter 11 bankruptcy protection after years of financial struggles and failed business pivots. The company, which was once valued at $6 billion, is now worth just $25 million as it grapples with a collapsing business model, cybersecurity concerns, and increasing regulatory scrutiny.

Founder Anne Wojcicki has stepped down as CEO effective immediately but will remain on the board. In her place, the company has appointed Joseph Selsavage as interim CEO as it navigates the bankruptcy process.

Wojcicki acknowledged the company’s challenges in a statement, saying, “There is no doubt that the challenges faced by 23andMe through an evolving business model have been real, but my belief in the company and its future is unwavering.”

Founded in 2006, 23andMe gained massive popularity with its at-home genetic testing kits, allowing customers to trace their ancestry and assess genetic health risks. The company’s early success led it to go public in 2021 through a special purpose acquisition company (SPAC) merger, which valued it at $3.5 billion.

However, the business struggled to generate recurring revenue beyond its one-time test kit sales. Attempts to transition into drug discovery and research partnerships failed to gain traction. Additionally, the company was hit with privacy concerns following a 2023 data breach that exposed the genetic information of nearly 7 million users, further damaging consumer trust.

According to court filings, 23andMe has between $100 million and $500 million in both estimated assets and liabilities. The company has stated that its primary goal is to sell its assets through a court-approved process over the next 45 days.

Wojcicki has indicated that she plans to be an independent bidder in the process, potentially seeking to take the company private after her previous takeover offers were rejected by 23andMe’s special committee.

Beyond financial troubles, the company continues to face scrutiny over its handling of sensitive consumer data. Last week, California Attorney General Rob Bonta issued a warning urging customers to reconsider keeping their genetic data stored with 23andMe, citing the risks of future breaches.

Despite these concerns, 23andMe has assured customers that there will be no immediate changes to how it stores or manages genetic data throughout the bankruptcy proceedings.

The future of 23andMe remains uncertain as the company seeks a buyer for its assets. While Wojcicki has signaled her interest in reclaiming control, potential bidders may be wary of the company’s financial instability and reputational damage.

For investors, this marks another cautionary tale of once-hyped SPAC deals that failed to deliver long-term value. As 23andMe fights for survival, the broader genetic testing industry must grapple with growing privacy concerns and the challenge of building sustainable business models beyond one-time test sales.

Gold’s Surge Revives Investor Interest in Mining Stocks

Key Points:
– Gold miners’ equity funds are seeing their largest net inflows in over a year as gold prices reach record highs.
– After years of cost struggles, major miners like Newmont and Barrick Gold are benefiting from increased profitability and stronger cash flows.
– Investors are turning back to mining stocks as a hedge against inflation and market uncertainty.

After months of outflows, investors are returning to gold mining stocks, buoyed by record-high gold prices that have improved the profit outlook for mining firms. With gold surpassing $3,000 an ounce this year—a gain of more than 15%—funds investing in gold miners saw their first net monthly inflow in six months this March, totaling $555.3 million, according to LSEG Lipper data.

While gold prices also climbed in 2024, gold miners faced mounting cost pressures from rising labor and fuel expenses, as well as regulatory setbacks like tax disputes in Mali and project delays in Canada. These challenges pushed many investors toward traditional gold funds instead of equities, leading to a net $4.6 billion outflow from gold miner-focused funds in 2024—the highest in a decade. Conversely, physical gold and gold derivative funds attracted $17.8 billion, the most in five years.

With rising gold prices boosting profitability, mining stocks are once again attracting investor interest. Leading companies like Newmont and Barrick Gold have recovered from last year’s declines, posting year-to-date gains of 27% and 21.5%, respectively. After facing cost pressures in recent years, gold mining firms are now in a stronger position to capitalize on higher gold prices, making them more appealing to investors.

The improved market conditions are prompting major gold miners to reward shareholders. Barrick Gold recently announced a $1 billion share buyback after reporting strong profits and doubling its free cash flow in Q4 2024. Similarly, AngloGold Ashanti declared a final dividend of 91 U.S. cents per share—nearly five times higher than the previous year—while Gold Fields hinted at a potential share buyback in 2025. Harmony Gold also revealed plans to self-fund the construction of a new copper mine in Australia.

With miners stabilizing operations and benefiting from higher gold prices, mining equities are increasingly viewed as an attractive investment. As market uncertainty and inflation persist, investors are showing renewed interest in gold mining stocks as a potential hedge and diversification strategy.

Given the miners’ historically low valuations, some analysts argue that gold mining stocks may present even better opportunities than gold itself. As confidence in gold miners grows alongside surging gold prices, these stocks may continue to attract investors seeking stability in an unpredictable market.

Smaller and junior gold mining companies stand to benefit significantly from this renewed investor interest in mining stocks. Unlike major miners, which already have strong cash flows and established operations, junior miners often struggle with financing new projects and navigating regulatory hurdles. However, with gold prices at record highs, investor appetite for higher-risk, high-reward opportunities may increase, providing these smaller companies with much-needed capital.

Higher gold prices also make previously unviable mining projects more attractive, allowing junior miners to push forward with exploration and development. Companies with promising gold reserves but lacking production capabilities may now find it easier to secure funding through equity offerings or partnerships with larger mining firms.

Additionally, with major miners focusing on share buybacks and dividends, they may look to acquire smaller mining companies to replenish their reserves, driving M&A activity in the sector. This could create lucrative exit opportunities for junior miners and early-stage investors.

Boeing Secures $20 Billion Contract for Next-Generation Fighter Jet

In a major boost to its defense business, Boeing has been awarded the contract to develop the U.S. Air Force’s next-generation fighter jet under the Next Generation Air Dominance (NGAD) program. The aircraft, now officially named the F-47, will replace the Lockheed Martin F-22 Raptor and is expected to serve alongside autonomous drone aircraft in future combat scenarios.

The announcement, made by President Donald Trump in the Oval Office, marks a critical turning point for Boeing, which has faced severe challenges in both its commercial and defense divisions. The engineering and manufacturing development contract, valued at over $20 billion, could ultimately yield hundreds of billions in future orders spanning multiple decades. Boeing’s victory over Lockheed Martin in securing this contract is a defining moment in the aerospace industry, shifting the balance of power in the defense sector.

The design and capabilities of the F-47 remain closely guarded secrets, but military officials have emphasized its advancements over the F-22 Raptor. Chief of Staff of the Air Force General David Allvin highlighted the F-47’s longer range, superior stealth capabilities, and increased adaptability to future threats. The aircraft is expected to feature cutting-edge avionics, enhanced sensors, and next-generation propulsion systems, making it a formidable asset in countering emerging threats from nations like China and Russia.

The NGAD initiative is envisioned as a “family of systems” incorporating manned and unmanned platforms to dominate future battlefields. The F-47 will play a pivotal role in this strategy, integrating seamlessly with artificial intelligence-driven drone squadrons to enhance operational efficiency and combat effectiveness.

Boeing’s stock surged 4% following the announcement, while Lockheed Martin’s shares dropped nearly 7%, reflecting investor sentiment regarding the shift in defense contracting priorities. For Boeing, this win represents a much-needed resurgence in its defense business, particularly after suffering major setbacks in commercial aviation, including production delays, safety concerns, and financial losses from the 737 MAX crisis.

Industry analysts view this contract as a significant validation of Boeing’s ability to execute high-stakes defense projects despite its recent challenges. Roman Schweizer, an analyst at TD Cowen, described the win as a “major boost” for Boeing, particularly given its struggles with cost overruns and delays on previous Department of Defense programs, including the KC-46 tanker and Air Force One modifications.

Lockheed Martin, meanwhile, faces an uncertain future in high-end fighter production. The company recently lost its bid to develop the Navy’s next-generation carrier-based stealth fighter, and this latest defeat raises questions about its long-term dominance in the military aviation sector. Despite these challenges, Lockheed continues to hold a strong position with its F-35 Lightning II program, which remains a critical component of U.S. and allied air forces.

Beyond domestic implications, the F-47 program may have significant international ramifications. Trump hinted that U.S. allies have already expressed interest in purchasing the aircraft, signaling potential foreign military sales that could further bolster Boeing’s defense revenue. Countries seeking advanced air superiority solutions may turn to the F-47 as a viable alternative to existing platforms, further extending its market potential.

While Lockheed may still have the option to challenge the contract award, the high-profile nature of Trump’s announcement makes such a move less likely. The public endorsement of Boeing’s selection could mitigate political or legal challenges, cementing the company’s role in shaping the future of American airpower.

As Boeing embarks on this ambitious defense project, the F-47 contract underscores the evolving landscape of military aviation, the growing reliance on next-generation technologies, and the shifting power dynamics within the aerospace industry. The coming years will reveal whether Boeing can successfully deliver on its promises and reestablish itself as a dominant force in the global defense market.

IQSTEL Expands Fintech Presence with GlobeTopper Acquisition

Key Points:
– IQSTEL signs MOU to acquire a 51% stake in fintech company GlobeTopper, strengthening its Fintech division.
– The deal accelerates IQSTEL’s revenue growth, pushing it closer to its $1 billion target by 2027.
– GlobeTopper’s integration with IQSTEL’s telecom network enhances cross-selling opportunities and market expansion.

IQSTEL Inc. (OTCQX: IQST), a rapidly expanding provider of Telecom, Fintech, Cybersecurity, and AI-driven services, has signed a Memorandum of Understanding (MOU) to acquire a 51% equity stake in GlobeTopper, LLC. This move bolsters IQSTEL’s fintech division and lays the groundwork for long-term revenue expansion.

Following its record $283 million revenue in 2024, IQSTEL projects $340 million in revenue for 2025, largely driven by its telecom division. The acquisition of GlobeTopper, a leader in B2B Top-Up solutions, is set to accelerate IQSTEL’s fintech growth, adding an estimated $60 million in revenue in 2025 and $85 million in 2026. The company aims to reach $1 billion in revenue by 2027, and this acquisition plays a critical role in achieving that milestone.

GlobeTopper’s preliminary 2024 financials show $39.4 million in revenue and $190,000 in EBITDA. IQSTEL will invest $1.2 million over 24 months to fuel further expansion, ensuring sustained growth in fintech services.

A major advantage of this acquisition is IQSTEL’s ability to integrate GlobeTopper’s fintech solutions within its extensive telecom network, spanning 21 countries and four continents. This cross-industry synergy will enable IQSTEL to unlock new high-margin revenue streams and provide added value to existing customers.

Additionally, GlobeTopper’s strong relationships with top-tier retail firms create new opportunities for IQSTEL to expand its service offerings. This partnership aligns with IQSTEL’s broader strategy of leveraging technology to diversify and enhance its business portfolio.

GlobeTopper’s CEO, Craig Span, will continue leading the company post-acquisition, ensuring stability and executing the company’s aggressive growth plans. IQSTEL’s President and CEO, Leandro Iglesias, emphasized the acquisition’s role in achieving IQSTEL’s ambitious revenue targets, stating that GlobeTopper’s fintech innovation and IQSTEL’s global telecom presence create a strong foundation for sustained expansion.

IQSTEL will acquire its 51% equity stake in GlobeTopper for $700,000, with a combination of cash payments and IQSTEL common shares. Additionally, the company will provide structured growth capital of up to $1.2 million over 24 months, contingent upon GlobeTopper achieving financial milestones.

This acquisition is a crucial step for IQSTEL in solidifying its fintech leadership while enhancing its overall business strength. As the company continues its aggressive expansion, shareholders can expect further developments in both the fintech and telecom sectors.

The Quantum Computing Revolution: Market Implications and Future Impact

Key Points:
– Quantum computing is advancing rapidly, with Nvidia launching a dedicated research center to collaborate with leading institutions and quantum firms.
– Quantum processors will complement, not replace, classical computing, accelerating advancements in AI, cryptography, pharmaceuticals, and financial services.
– Investment in quantum technology is growing, positioning it as a long-term market opportunity with transformative industry-wide effects.

Quantum computing, once considered a futuristic concept, is rapidly evolving into a tangible force in the tech industry. Nvidia’s recent announcement of its quantum computing research lab, the Nvidia Accelerated Quantum Research Center (NVAQC), marks a major milestone in the sector. Partnering with Harvard, MIT, and key quantum firms like Quantinuum and QuEra Computing, Nvidia aims to advance quantum computing capabilities and bridge the gap between classical and quantum systems. The implications of these advancements could be transformative across multiple industries, particularly in artificial intelligence, cybersecurity, pharmaceuticals, and finance.

The State of Quantum Computing Today

While Nvidia CEO Jensen Huang previously downplayed the near-term viability of quantum computing, he has since adjusted his stance, acknowledging the growing role of quantum technologies. The industry has already begun finding real-world applications, with firms like IonQ and Infleqtion developing quantum-enhanced solutions for optimization, materials science, and complex simulations. Despite the challenges of scaling quantum hardware, these companies are proving that quantum technologies can generate commercial value even before reaching full-scale quantum supremacy.

One major takeaway from Nvidia’s recent event was the consensus that quantum computers will not replace classical systems but rather complement them. Quantum processors will serve as accelerators for specialized tasks, working alongside traditional computing infrastructure to unlock new levels of efficiency and performance.

Investment and Market Potential

The quantum computing industry is attracting significant investment, with major tech giants such as Google, Microsoft, and IBM pouring billions into research and development. Nvidia’s strategic involvement signals that quantum computing is becoming too important for leading semiconductor and AI companies to ignore. While practical, large-scale quantum computers remain years away, investors are increasingly viewing the sector as a long-term growth opportunity.

Publicly traded quantum firms, such as IonQ and D-Wave, are beginning to establish themselves in the market despite initial skepticism. Nvidia’s acknowledgment of their potential has helped restore confidence after previous comments led to stock declines. As breakthroughs continue, institutional investors and venture capital firms will likely increase their exposure to the sector, driving further innovation.

Implications for Key Industries

The impact of quantum computing will be profound across various industries, reshaping technological capabilities and business strategies. In artificial intelligence and machine learning, quantum computing can significantly enhance model training and optimization, leading to advancements in natural language processing, robotics, and deep learning applications. By processing vast amounts of data more efficiently, quantum technology could unlock new possibilities in AI-driven automation and predictive analytics.

In cybersecurity and cryptography, quantum computing presents both opportunities and risks. Quantum cryptography promises to revolutionize data security with encryption methods that are virtually unbreakable by classical computers. However, it also poses a challenge to current encryption standards, requiring organizations to develop quantum-resistant security measures to protect sensitive information in the digital age.

The pharmaceutical and healthcare sectors stand to benefit immensely from quantum computing’s ability to model molecular interactions with unprecedented precision. This capability could lead to faster drug discoveries, improved treatment options, and personalized medicine breakthroughs. Quantum simulations could help researchers identify new compounds and predict their effects, accelerating the development of life-saving drugs.

Financial services and investment firms will also experience a paradigm shift with quantum computing. The ability to optimize complex financial models, perform rapid risk assessments, and enhance portfolio management strategies will give hedge funds and banks a competitive edge. Quantum algorithms could help institutions navigate market volatility and identify profitable investment opportunities with greater accuracy than traditional computing methods.

Looking Ahead

Despite ongoing challenges in hardware development, the quantum computing industry is making steady progress toward commercialization. Nvidia’s growing commitment to quantum research suggests that leading tech firms recognize the importance of positioning themselves early in this emerging field. As quantum technologies continue to mature, their impact on market sectors will become increasingly profound, reshaping how businesses and economies operate.

The coming years will determine whether quantum computing achieves its full disruptive potential, but one thing is certain: the industry is no longer a speculative science fiction concept—it’s an innovation frontier with real-world implications. Investors, enterprises, and policymakers should pay close attention to its development, as quantum computing is poised to be one of the most transformative technologies of the 21st century.

CoreWeave Launches $2.7 Billion IPO Amid AI Cloud Boom

Key Points:
– Nvidia-backed AI cloud firm aims for a $32B valuation with shares priced at $47-$55.
– Once a crypto-mining firm, CoreWeave now dominates AI cloud services, with Microsoft driving most of its revenue.
– Despite backing from Cisco and JPMorgan, CoreWeave faces high losses and financial control concerns.

CoreWeave Inc., a cloud-computing firm specializing in AI infrastructure, has announced plans for an initial public offering (IPO) aimed at raising as much as $2.7 billion. The Nvidia-backed company, along with some of its investors, is marketing shares at a price range of $47 to $55, which would give CoreWeave a market value of approximately $26 billion based on outstanding shares. If fully diluted, the valuation could reach as high as $32 billion.

Founded in 2017 as a crypto-mining firm, CoreWeave has rapidly transitioned into a leading provider of cloud-based AI solutions. The company has established itself as a crucial player in AI computing by leveraging Nvidia’s high-performance GPUs to power data centers. This strategic positioning has allowed it to secure major customers, including Microsoft, which accounted for nearly two-thirds of its 2024 revenue.

CoreWeave reported revenue of $1.9 billion in 2024, a massive jump from $229 million in the prior year. However, the company is still operating at a loss, with a net deficit of $863 million last year compared to $594 million in 2023. The high concentration of revenue from a small number of clients—77% of 2024 revenue coming from just two customers—remains a potential risk factor for investors.

Ahead of its public listing, CoreWeave has sealed significant partnerships, including a deal to provide AI infrastructure to OpenAI worth up to $11.9 billion. Additionally, the company is set to acquire AI developer platform Weights & Biases for approximately 1 million Class A shares, a move expected to enhance its cloud capabilities.

Despite its rapid expansion, CoreWeave faces challenges related to internal financial controls. In its IPO filings, the company disclosed “material weaknesses” in IT controls and a shortage of qualified personnel in financial reporting. Addressing these issues will be crucial as it transitions into a publicly traded company.

The IPO comes amid heightened investor interest in AI-driven cloud infrastructure. CoreWeave has attracted backing from prominent firms including Magnetar Capital, Coatue Management, Jane Street, Fidelity, and Lykos Global Management. Notably, Cisco Systems recently invested in CoreWeave as part of a transaction valuing the company at $23 billion.

Following the IPO, CEO Michael Intrator is expected to hold 37% of shareholder voting power through his control of Class B shares. Nvidia, a key investor, will retain 1.2% of voting power, while Magnetar will hold 7%.

The offering is being led by Morgan Stanley, JPMorgan, and Goldman Sachs, with CoreWeave shares set to trade under the ticker symbol CRWV on the Nasdaq. The outcome of this IPO will serve as a critical indicator of investor appetite for AI-focused cloud firms and could set the stage for further public offerings in the sector.